Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Stock Has Consensus Target Price of $4.00 According to Analysts

Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) have earned an average recommendation of “Moderate Buy” from the seven ratings firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $4.00.

TNYA has been the topic of several research analyst reports. Wall Street Zen upgraded shares of Tenaya Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, September 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Tenaya Therapeutics in a research report on Monday, October 26th.

Institutional Investors Weigh In On Tenaya Therapeutics

Institutional investors have recently bought and sold shares of the company. BlackRock Inc. acquired a new position in shares of Tenaya Therapeutics during the second quarter valued at approximately $2,963,000. Empery Asset Management LP purchased a new position in shares of Tenaya Therapeutics in the second quarter valued at approximately $2,855,228. Renaissance Technologies LLC lifted its position in shares of Tenaya Therapeutics by 100.6% in the first quarter. Renaissance Technologies LLC now owns 3,713,761 shares of the company’s stock valued at $2,571,000 after acquiring an additional 1,862,894 shares in the last quarter. GSA Capital Partners LLP purchased a new position in shares of Tenaya Therapeutics in the second quarter valued at approximately $1,973,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Tenaya Therapeutics in the second quarter worth approximately $1,150,000. 90.54% of the stock is currently owned by institutional investors and hedge funds.

Tenaya Therapeutics Stock Performance

Shares of NASDAQ TNYA opened at $0.37 on Friday. The firm has a market cap of $83.74 million, a PE ratio of -0.69 and a beta of 2.87. The firm has a fifty day moving average of $0.57 and a 200 day moving average of $0.71. Tenaya Therapeutics has a one year low of $0.36 and a one year high of $1.56.

Tenaya Therapeutics (NASDAQ:TNYA) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.13). The business had revenue of $1.11 million for the quarter, compared to the consensus estimate of $10.00 million. On average, equities analysts predict that Tenaya Therapeutics will post -0.38 EPS for the current fiscal year.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for genetic and other serious diseases of the heart. The company combines gene therapy, gene editing, cell therapy and small-molecule drug discovery technologies to target the underlying causes of cardiovascular disease rather than treating symptoms alone.

Tenaya’s pipeline has included TN-201, an adeno-associated virus gene replacement therapy being developed for patients with MYBPC3-associated hypertrophic cardiomyopathy, and TN-401, a gene therapy candidate designed for PKP2-associated arrhythmogenic right ventricular cardiomyopathy.